COLL Collegium Pharmaceutical Inc
Price (delayed)
$36.2
Market cap
$1.17B
P/E Ratio
11.95
Dividend/share
N/A
EPS
$3.03
Enterprise value
$1.55B
Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.
Highlights
COLL's P/E is 64% below its last 4 quarters average of 33.0
Collegium Pharmaceutical's gross profit has increased by 37% YoY and by 5% QoQ
The equity is up by 8% year-on-year but it is down by 2.5% since the previous quarter
The quick ratio has declined by 13% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of COLL
Market
Valuations
Earnings
Shares outstanding
32.21M
Market cap
$1.17B
Enterprise value
$1.55B
Price to earnings (P/E)
11.95
Price to book (P/B)
5.47
Price to sales (P/S)
2.04
EV/EBIT
7.24
EV/EBITDA
4.27
EV/Sales
2.69
Revenue
$576.65M
EBIT
$214.19M
EBITDA
$363.6M
Free cash flow
$275.62M
Per share
Balance sheet
Liquidity
EPS
$3.03
Free cash flow per share
$8.5
Book value per share
$6.62
Revenue per share
$17.78
TBVPS
$17.48
Total assets
$1.05B
Total liabilities
$836.81M
Debt
$559.46M
Equity
$216.58M
Working capital
$48.48M
Debt to equity
2.58
Current ratio
1.11
Quick ratio
0.99
Net debt/EBITDA
1.06
Margins
Efficiency
Dividend
EBITDA margin
63.1%
Gross margin
61.9%
Net margin
17.3%
Operating margin
35.3%
Return on assets
8.9%
Return on equity
49.1%
Return on invested capital
39.2%
Return on capital employed
36.2%
Return on sales
37.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COLL stock price
How has the Collegium Pharmaceutical stock price performed over time
Intraday
0.36%
1 week
-5.33%
1 month
1.97%
1 year
54.97%
YTD
17.61%
QTD
12.42%
Financial performance
How have Collegium Pharmaceutical's revenue and profit performed over time
Revenue
$576.65M
Gross profit
$357.2M
Operating income
$203.65M
Net income
$99.89M
Gross margin
61.9%
Net margin
17.3%
Collegium Pharmaceutical's operating income has surged by 120% YoY and by 6% QoQ
Collegium Pharmaceutical's operating margin has surged by 105% YoY and by 4.4% QoQ
Collegium Pharmaceutical's gross profit has increased by 37% YoY and by 5% QoQ
The gross margin rose by 28% year-on-year and by 3.2% since the previous quarter
Growth
What is Collegium Pharmaceutical's growth rate over time
Valuation
What is Collegium Pharmaceutical stock price valuation
P/E
11.95
P/B
5.47
P/S
2.04
EV/EBIT
7.24
EV/EBITDA
4.27
EV/Sales
2.69
COLL's P/E is 64% below its last 4 quarters average of 33.0
Collegium Pharmaceutical's EPS has increased by 8% from the previous quarter
The price to book (P/B) is 30% higher than the 5-year quarterly average of 4.2 and 9% higher than the last 4 quarters average of 5.0
The equity is up by 8% year-on-year but it is down by 2.5% since the previous quarter
COLL's price to sales (P/S) is 13% higher than its last 4 quarters average of 1.8 and 2% higher than its 5-year quarterly average of 2.0
The revenue is up by 7% year-on-year
Efficiency
How efficient is Collegium Pharmaceutical business performance
Collegium Pharmaceutical's ROS has soared by 159% YoY
The company's return on assets rose by 11% QoQ
The ROIC has grown by 9% from the previous quarter
The ROE is up by 4.9% QoQ
Dividends
What is COLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COLL.
Financial health
How did Collegium Pharmaceutical financials performed over time
Collegium Pharmaceutical's total assets is 26% more than its total liabilities
Collegium Pharmaceutical's total liabilities has decreased by 17% YoY and by 6% QoQ
Collegium Pharmaceutical's total assets has decreased by 13% YoY and by 5% from the previous quarter
COLL's debt is 158% greater than its equity
The debt to equity fell by 32% YoY and by 9% QoQ
COLL's debt is down by 27% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.